Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Dermatology 2003;206:316–320

A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin C Iontophoresis in Melasma

Huh C.-H.a · Seo K.-I.b · Park J.-Y.a · Lim J.-G.a · Eun H.-C.a · Park K.-C.a

Author affiliations

aDepartment of Dermatology, Seoul National University College of Medicine, and bModelo Clinic, Seoul, Korea

Corresponding Author

Prof. Kyung-Chan Park, MD, PhD

Department of Dermatology, Seoul National University College of Medicine

28, Yongon-dong, Chongno-gu

Seoul 110-744 (Korea)

Tel. +82 2 3668 7474, Fax +82 2 742 7344, E-Mail gcpark@snu.ac.kr

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background: Vitamin C is known to both inhibit melanin formation and reduce oxidized melanin. However, vitamin C does not easily penetrate the skin. In this study, vitamin C iontophoresis was employed in order to enhance vitamin C penetration. Objective: The purpose of this study was to evaluate the efficacy of vitamin C iontophoresis for melasma patients. Methods: Twenty-nine females with melasma were enrolled. For iontophoresis, a vitamin C solution was applied to one side of the face, while distilled water was applied to the other side as a control. The L (luminance) value was measured by a colorimeter to obtain an objective pigmentation parameter. Results: Twelve weeks after iontophoresis, the colorimeter of the treated site showed a significant decrease in the L value (from 4.60 to 2.78, p = 0.002), compared to that of the control site (from 4.45 to 3.87, p = 0.142). Conclusion: Vitamin C iontophoresis may be an effective treatment modality for melasma.

© 2003 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Pharmacology and Treatment

Received: January 08, 2002
Accepted: October 05, 2002
Published online: June 13, 2003

Number of Print Pages: 5
Number of Figures: 5
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.